Expert Of Animal Models In Autoimmune Diseases

HKeyBio is your preclinical CRO partner especially in autoimmune diseases field.

HKeybio offers more than 100 autoimmune-disease animal models in 7 categories relying on the rodent labs in Suzhou and non-human primate labs in Guangxi. These models can be used in in-vivo studies relevant to various pathogeneses and clinical subtypes of dozens of autoimmune diseases.

Your Consultant Of Drug Development Strategy Based On Drug Targets & Clinical Features Of Diseases

HKeybio has successfully helped our customers in pre-IND studies in China and abroad. We have experience in hundreds of drugs or therapies such as small molecules, mAbs, multispecific antibodies, ADCs, cell and gene therapies. We work 24×7 and will initiate your studies in 7 days.

Professional Animal Model Services

Delayed type hypersensitivity reaction View More

Rheumatoid Arthritis-NHP View More

Atopic Dermatitis-NHP View More

Alopecia areata View More

Uveitis (EAU-EIU) -NHP View More

Rheumatoid Arthritis View More

Radiation dermatitis View More

Acute graft-versus-host disease View More

Myasthenia Gravis-NHP View More

Systemic Lupus Erythematosus View More

Inflammatory bowel disease View More

Vitiligo View More

Chronic graft-versus-host disease View More

Post-Surgery Pain View More

Idiopathic Pulmonary Fibrosis-NHP View More

Uveitis View More

Psoriasis-NHP View More

Inflammatory Bowel Disease-NHP View More

Eosinophilic esophagitis View More

Sjogren's Syndrome-NHP View More

KNOWLEDGE OF DISEASES

Disease Mechanism Disease

Characterization

Animal Model

Model Analysis

View More
EXPERIENCED IN PHARMACEUTICS

Study Design Experience
Communication
Documents For IND Registration

View More
PACKAGED SOLUTION

PK, PD, Tox Research
PK/PD, TK Evaluation
Integrated Pre-Clinical Study Plan

View More
PRECISE PROBLEM SOLVING

Target Based Biomarker Development
Unique Requirement Of Novel Drugs

View More

High-Tech Enterprise Specializes In Autoimmune Animal Models

HKeybio is a Contract Research Organization (CRO) specializing in preclinical research within the field of autoimmune diseases. The company operates a small animal and detection test facility in Suzhou Industrial Park, as well as a non-human primate test base in Guangxi. The founding team members each have extensive preclinical experience, with backgrounds in large international pharmaceutical companies totaling nearly 20 years.

+ years

Of experience in new drug development from our core team

Validated animal models

relevant to

Autoimmune-disease

Medicine Solutions With Personalized Customization

PRE-CLINICAL

RESEARCH

Learn More

Novel DDS Antibodies Cellular

Novel DDS

Client Background: Our client is a pharmaceutical company that has developed a novel compound designed to target mitochondrial damage-related autophagy and possess neuroregenerative properties. The client aims to explore the potential therapeutic effects of their compound in an autoimmune-mediated disease.

Problem Statement: The client sought to establish the efficacy of their compound in appropriate neurologically related autoimmune diseases.

Learn More
Antibodies

Client case: Development of a Novel Antibody Drug Targeting IL-25 for Atopic Dermatitis(AD).

Client: A pharmaceutical company developing a new antibody targeting the IL-25 pathway for the

treatment of AD

Objective: To establish the efficacy and safety of the new anti-IL-25 antibody in preclinical models of atopic dermatitis, compared to a standard positive drug control.

Learn More
Cellular
Therapy

Client case: Development of a Novel Antibody Drug Targeting IL-25 for Atopic Dermatitis(AD).

Client: A pharmaceutical company developing a new antibody targeting the IL-25 pathway for the
treatment of AD

Objective: To establish the efficacy and safety of the new anti-IL-25 antibody in preclinical models of atopic dermatitis, compared to a standard positive drug control.
Learn More
Gene
Therapy

Client case: Development of a Novel Antibody Drug Targeting IL-25 for Atopic Dermatitis(AD).

Client: A pharmaceutical company developing a new antibody targeting the IL-25 pathway for the
treatment of AD

Objective: To establish the efficacy and safety of the new anti-IL-25 antibody in preclinical models of atopic dermatitis, compared to a standard positive drug control.
Learn More
XDCS

Client case: Development of a Novel Antibody Drug Targeting IL-25 for Atopic Dermatitis(AD).

Client: A pharmaceutical company developing a new antibody targeting the IL-25 pathway for the
treatment of AD

Objective: To establish the efficacy and safety of the new anti-IL-25 antibody in preclinical models of atopic dermatitis, compared to a standard positive drug control.
Learn More
Small
Moleculars

Client case: Development of a Novel Antibody Drug Targeting IL-25 for Atopic Dermatitis(AD).

Client: A pharmaceutical company developing a new antibody targeting the IL-25 pathway for the
treatment of AD

Objective: To establish the efficacy and safety of the new anti-IL-25 antibody in preclinical models of atopic dermatitis, compared to a standard positive drug control.
Learn More
Vaccines

Client case: Development of a Novel Antibody Drug Targeting IL-25 for Atopic Dermatitis(AD).

Client: A pharmaceutical company developing a new antibody targeting the IL-25 pathway for the
treatment of AD

Objective: To establish the efficacy and safety of the new anti-IL-25 antibody in preclinical models of atopic dermatitis, compared to a standard positive drug control.
Learn More
Microbiota

Client case: Development of a Novel Antibody Drug Targeting IL-25 for Atopic Dermatitis(AD).

Client: A pharmaceutical company developing a new antibody targeting the IL-25 pathway for the
treatment of AD

Objective: To establish the efficacy and safety of the new anti-IL-25 antibody in preclinical models of atopic dermatitis, compared to a standard positive drug control.
Learn More

Not Only A Supplier But Also Your Reliable Target Validation Partner

CIA Model: A Key Tool for Analyzing Autoimmune Response

2025-07-17

CIA Model: A Key Tool for Analyzing Autoimmune ResponseAutoimmune diseases, characterized by the immune system's abnormal attack on the body's own tissues, have become a global health challenge.

2025-07-17

CIA Model: Innovative Applications of Collagen II Induced

2025-07-24

CIA Model: Innovative Applications of Collagen II InducedIn the dynamic field of life science research, the construction of disease models stands as a pivotal cornerstone.

2025-07-24

CIA Model: The Key To Unveiling The Mechanisms of Multisystem Damage in Rheumatoid Arthritis

2025-07-31

CIA Model: The Key to Unveiling the Mechanisms of Multisystem Damage in Rheumatoid ArthritisRheumatoid arthritis (RA) is not merely a disorder confined to the joints; it is a complex, chronic inflammatory condition with far - reaching consequences.

2025-07-31

Professional Animal Model Services

High-Tech Enterprise Specializes In Autoimmune Animal Models

Medicine Solutions With Personalized Customization

Not Only A Supplier But Also Your Reliable Target Validation Partner

CIA Model: A Key Tool for Analyzing Autoimmune Response

CIA Model: Innovative Applications of Collagen II Induced

CIA Model: The Key To Unveiling The Mechanisms of Multisystem Damage in Rheumatoid Arthritis

Quick Links

Service Catagory

Contact Us